The Joint Chiropractic account plan
Chiropractic care accessibility and improvement
At a glance
The Joint Corp. franchises The Joint Chiropractic, a cash-based US chiropractic chain with 930 clinics and $532.4 million of 2025 system-wide sales.
The Joint Corp. (Nasdaq: JYNT), headquartered in Scottsdale, Arizona, franchises The Joint Chiropractic clinics: retail-center chiropractic offices that need no appointment and use a private-pay, non-insurance, cash-based model aimed at non-acute care. It calls itself the largest chiropractic franchisor in the United States, with 960 clinics in 43 states at December 31, 2025 and 930 clinics at September 30, 2026 (915 franchised, 15 company-owned or managed). In 2025, system-wide sales were $532.4 million across 14.4 million patient visits, GAAP revenue from continuing operations rose 5.2% to $54.9 million and net income was $2.9 million. The company had approximately 202 full-time and 128 part-time employees at December 31, 2025, and more than 2,500 licensed chiropractic doctors work in the network. Under its "Joint 2.0" strategy it has sold nearly all company-owned clinics to become a capital-light, pure-play franchisor.
Business units
Franchise Operations
$54.9 million revenue in 2025 (continuing operations)The only reportable segment since the fourth quarter of 2024: royalty fees ($33.2 million in 2025), advertising fund revenue, software fees and franchise fees from 885 franchised clinics at end-2025 (915 at September 30, 2026). Franchises are sold directly and through regional developers, whose territories the company is now buying back. Q3 2026 revenue rose 1.3% to $13.6 million; it is led by the CEO as chief operating decision maker.
Corporate Clinics (discontinued operations)
$54.0 million revenue in 2025, down from $70.0 millionCompany-owned or managed clinics being sold to franchisees and multi-unit operators in geographic clusters, reported as discontinued operations. The count fell from 75 clinics at end-2025 to 15 at September 30, 2026 after sales in Southern California, Northern California and the Southeast. Revenue of the discontinued clinics fell to $4.2 million in Q3 2026 (from $10.5 million).
Strategic priorities
- Complete the pure-play franchisor model (Joint 2.0)
- Refranchising of all company-owned or managed clinics is substantially complete, with 15 left at September 30, 2026. The target model is G&A at 40%-42% of revenue, gross margin 83%-85% and Adjusted EBITDA margin 19%-21% (12% in 2025).
- Improve comp sales in 2027
- Comp sales were -4.2% in Q1, -2.8% in Q2 and -1.9% in Q3 2026; the CEO calls improving them the single priority for 2027, through new patient acquisition, conversion, retention and win-back of lapsed patients.
- Grow new patients and active members
- Marketing pivoted from wellness to pain relief and from local to national media from November 2025, with SEO work for AI-driven search; flexible AlignOne and AlignTwo membership plans aim to raise conversion and retention.
- Buy back regional developer territories
- Five territories with 189 franchised clinics, including Texas, were reacquired in 2026, worth approximately $3.0 million of annual RD royalty savings, about one-third offset by internal costs; the company will keep evaluating further buybacks.
- Return to clinic growth
- After closing underperforming clinics in 2026 (year-end count about 50 clinics lower than 2025), management expects clinic growth to resume in 2027, citing potential for more than 1,800 clinics in the U.S. and 150+ potential clinics in the reacquired territories.
- Joint 3.0: new channels and markets
- From 2027 the next phase is to add new channels, B2B, underpenetrated US markets and first international markets, with positioning on longevity, nutrition, orthotics and wearables data.
Latest results
In Q3 2026 (quarter ended September 30, 2026), revenue from continuing operations rose 1.3% to $13.6 million while system-wide sales fell 3.1% to $123.3 million and comp sales decreased 1.9% (after -2.8% in Q2 2026). Net income from continuing operations rose to $1.5 million (vs $0.3 million) and Adjusted EBITDA from continuing operations to $2.3 million (vs $1.4 million), but discontinued operations lost $1.6 million, leaving a consolidated net loss of $0.1 million. G&A fell to 51% of revenue (55% a year earlier). Over nine months, revenue rose 9.6% to $43.6 million. The company cut its 2026 guidance to system-wide sales of $508-$512 million (from $519-$552 million) and comp sales of -3.5% to -2.5%, citing "continued macroeconomic pressures on consumer spending", while keeping consolidated Adjusted EBITDA at $12.5-$13.5 million.
Investments and deals
- Refranchising of corporate clinics
- June 2025: 31 Arizona and New Mexico clinics sold to Joint Ventures, LLC for $8.3 million; December 2025: 22 Southeast clinics for approximately $1.5 million; April 20, 2026: 45 Southern California clinics to Elite Chiro Group for $2.3 million; June 28, 2026: four Northern California clinics to Vigeo, LLC for $400 thousand.
- Texas regional developer buyback
- On October 1, 2026 the company reacquired the Texas regional development rights (141 franchised clinics) for $8.0 million in cash plus up to $2.0 million tied to gross sales over two years.
- AI-powered lead management platform
- A new lead management platform supported by 6 AI agents launches in January 2027 to follow up on leads, book appointments and answer frequently asked questions; it should begin contributing to comps during 2027.
- Share repurchases
- $11.3 million of buybacks in 2025 under a $17.0 million program and $5.6 million in the first nine months of 2026; the program was exhausted at September 30, 2026 and the board authorized $5.0 million more on November 3, 2026.
- Marketing technology and point of sale
- Growth projects held to a 25% IRR hurdle include reworking and bringing in-house the MarTech stack and a consolidated point-of-sale interface for wellness coordinators; the mobile app adds wait times, in-app registration and patient recognition features.
Challenges and risks
- Fewer new patients and lower spend
- New patients fell to 797,100 in 2025 from 957,000; in Q3 2026 pressure on consumer spending led to fewer new patients and lower average patient spend per month, and flexible plans dilute spend by about $2 per patient per month.
- Consumer sensitivity to the economy
- Maintenance chiropractic is a discretionary expense; patients' household income is mostly $60,000-$110,000, so the 2026 guidance includes no price increase, and management cites inflation, gas prices and elevated interest rates.
- Chiropractor shortage and labor costs
- The 10-K names a nationwide shortage of chiropractors and labor-cost inflation, including minimum wage increases from January 1, 2026, as the main inflationary factor.
- Shrinking network and slower franchise sales
- Only one franchise license was sold in Q3 2026 (13 a year earlier), licenses sold but not yet developed fell to 47 from 86, and 37 franchised clinics closed in nine months.
- Regulation and franchise risk
- State rules on the corporate practice of chiropractic, joint-employer rules, dependence on independent franchisees and regional developers, and data privacy and cybersecurity are named risks.
What leadership says
“Our third quarter results show that the actions we have taken to strengthen patient engagement and reshape our operating model are beginning to work together.”
“We are single mindedly focused on improving comp sales.”
“a highly efficient, capital-light pure-play franchisor with more consumer touch points and with strong free cash flow generation.”
“new patient flow has been the weakest for us”
Where a supplier can help
- Patient acquisition and AI search visibility
- Tied to the new-patient challenge and the marketing pivot: suppliers of local and national media, SEO for AI-driven search and lead conversion tools can support the push to grow new patients and comp sales in 2027.
- Retention, membership and app engagement
- Tied to the comp sales priority: win-back campaigns, automated messaging, loyalty and app features help keep members longer, which the company says costs less than acquiring new patients.
- Franchise development and site selection
- Tied to the return to clinic growth: franchise recruitment, site selection and pre-opening marketing services fit the plan to resume openings in 2027 and develop the 150+ potential clinics in reacquired territories.
- Chiropractor recruiting and workforce tools
- Tied to the chiropractor shortage and labor-cost challenge: recruiting, scheduling and labor-efficiency tools for the network address the main inflationary factor management names.
- Retail products and longevity offerings
- Tied to Joint 3.0: the company is piloting orthotics and nutritional supplements and considering wearables data, opening room for product and technology partners.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like The Joint Chiropractic?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for the fiscal year ended December 31, 2025
- The Joint Corp. (Nasdaq: JYNT) is the largest chiropractic franchisor in the United States: 960 clinics in 43 states at December 31, 2025 (885 franchised, 75 company-owned or managed), a private-pay, non-insurance, cash-based, appointment-free model.
- 2025 system-wide sales were $532.4 million (flat on a percentage basis) across 14.4 million patient visits (14.7 million in 2024); Comp Sales were flat; new patients fell to 797,100 from 957,000.
- GAAP revenue from continuing operations (Franchise Operations) rose 5.2% to $54.9 million: royalty fees $33.2 million, advertising fund revenue $10.5 million, software fees $6.0 million, franchise fees $3.4 million.
- Net income was $2.9 million (vs a $5.8 million loss in 2024); Adjusted EBITDA from net operations was $13.0 million, of which $3.1 million from continuing operations.
- Strategy: become a pure-play franchisor by selling all company-owned or managed clinics; 41 clinics divested in 2025 and 22 more under an Asset Purchase Agreement. The Corporate Clinics segment ($54.0 million revenue in 2025) is reported as discontinued operations.
- Growth levers: grow active patients (intake, initial-visit appointments, local marketing, reactivating lapsed patients), sell franchises through 15 regional developers, open 82 licenses sold but not yet developed, and add products such as nutraceuticals.
- Capital allocation: $11.3 million of buybacks in 2025 under a $17.0 million program; $23.6 million cash and $20.0 million undrawn JPMorgan Chase credit facility.
- New leadership: CEO Sanjiv Razdan (since October 2024, ex-Coffee Bean & Tea Leaf, Sweetgreen, Applebee's, Yum!), CFO Scott J. Bowman (June 2025), CMO Debbie Gonzalez (October 2025), SVP Operations Ron Stilwell (January 2026).
- Key risks: shortage of chiropractors and wage inflation, discretionary consumer spending, dependence on franchisees and regional developers, state corporate-practice-of-chiropractic rules, joint-employer rules, data privacy.
- Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 revenue (continuing operations, Franchise Operations) rose 1.3% to $13.6 million; nine-month revenue rose 9.6% to $43.6 million.
- System-wide sales fell 3.1% to $123.3 million in Q3 and Comp Sales decreased 1.9%.
- Net income from continuing operations $1.5 million in Q3 (vs $0.3 million); consolidated net loss $0.1 million after discontinued-operation losses. Adjusted EBITDA from continuing operations $2.3 million (vs $1.4 million).
- 930 clinics at September 30, 2026: 915 franchised and only 15 company-owned or managed (78 a year earlier); 47 licenses sold but not yet developed.
- Refranchising nearly done: 45 Southern California clinics sold to Elite Chiro Group for $2.3 million, 4 Northern California clinics to Vigeo, and the 22-clinic Southeast deal partly closed.
- Regional developer buybacks: four territories bought back by mid-2026 and Texas (141 franchised clinics) on October 1, 2026 for $8.0 million plus up to $2.0 million earn-out.
- Only one franchise license sold in Q3 (13 a year earlier); 11 regional developers remain.
- G&A fell to 51% of revenue in Q3 (55% a year earlier); cost of revenues fell 9.7% on lower regional developer royalties.
- $5.6 million of buybacks in nine months; the 2025 SRP was exhausted and $5.0 million more authorized on November 3, 2026; unrestricted cash $18.3 million.
- The Joint Corp. Reports Third Quarter 2026 Financial Results (press release, Exhibit 99.1)
- Q3 2026 revenue rose 1% to $13.6 million; system-wide sales fell 3.1% to $123.3 million; comp sales -1.9% (vs -2.8% in Q2 2026).
- Net income from continuing operations rose to $1.5 million and Adjusted EBITDA from continuing operations to $2.3 million; consolidated Adjusted EBITDA flat at $3.3 million.
- 2026 guidance cut: system-wide sales $508-$512 million (from $519-$552 million) and comp sales -3.5% to -2.5% (from -3% to 3%); consolidated Adjusted EBITDA kept at $12.5-$13.5 million.
- Year-end 2026 clinic count expected about 50 clinics lower than 2025 as underperforming clinics close.
- Five regional developer territories (189 franchised clinics, including Texas) reacquired in 2026, worth approximately $3.0 million of annual RD royalty savings, about one-third offset by internal costs.
- Refranchising under the "Joint 2.0" strategy substantially complete: the company "now operates as a capital-light, pure-play franchisor".
- CEO Sanjiv Razdan: growth in active members and lifetime value, offset by lower spend per month and fewer new patients; flexible membership options keep members longer.
- $3.8 million of buybacks in Q3 at $8.30 average; additional $5 million authorized; $20 million undrawn credit line through August 2029.
- The Joint (JYNT) Q3 2026 Earnings Call Transcript
- Sanjiv Razdan (CEO) and Scott Bowman (CFO) on Q3 2026: actions on patient engagement and the operating model "are beginning to work together", but the consumer environment weighs on spending and comps.
- Comp sales -1.9% in Q3, improving from -2.8% in Q2 and -4.2% in Q1; active members per clinic up year on year and versus Q2; months and dollars per active member up.
- Flexible lower-frequency plans (1 and 2 visits a month) lift conversion and retention but dilute spend by roughly $2 per patient per month; patients' household income is "somewhere between 60 thousand to $110 thousand".
- New AI-powered lead management platform with 6 AI agents launching in January 2027; AI visibility score in the mid-70s.
- New clinics: 2026 openings break even in about 3 months vs about 18 months historically; franchise broker network signed; 150+ potential clinics in the five reacquired RD territories.
- Longevity/health span positioning: mobility scores, proprietary care protocols, piloting orthotics and nutritional supplements.
- Pure-play model starting points: gross margin 83%-85%, G&A 40%-42% of revenue, Adjusted EBITDA margin 19%-21%; RD buybacks recapture about two-thirds of royalties paid to developers.
- 2027 priority: "We are single mindedly focused on improving comp sales." Clinic growth to resume next year.
- The Joint (JYNT) Q4 2025 Earnings Call Transcript
- Sanjiv Razdan (CEO) on Q4/FY2025 (March 12, 2026): "Joint 2.0", the first transformation phase, is on track to complete by the end of 2026; refranchising left 48 corporate clinics from 135 at the start.
- FY2025: system-wide sales $532 million flat, comp sales -0.4%, consolidated Adjusted EBITDA up 14% to $13,000,000; Q4 comp sales down 3.8%.
- Initial 2026 guidance: system-wide sales $540-$552 million, comp sales -3% to +3%, consolidated Adjusted EBITDA $12,500,000 to $13,500,000; net clinic count to fall in 2026; potential for more than 1,800 US clinics.
- Pure-play franchisor model (from mid-2026): revenue about 11% of system-wide sales, G&A 40%-42% of revenue (64% in 2025), Adjusted EBITDA margin 19%-21% (12% in 2025); 25% IRR hurdle for growth capex.
- Marketing pivot from wellness to pain relief, shift from local to national media (from November 2025) and SEO for AI-driven search; new patients are "the weakest" component of active member growth.
- Pricing tests of $2, $5 and $10 increases in about 300 clinics; AlignOne low-frequency plan at $35 a month, AlignTwo in test.
- "Joint 3.0" from 2027: new channels, B2B, underpenetrated US markets and first international markets; longevity, wearables data, nutrition and orthotics.
Questions about The Joint Chiropractic
What does The Joint Corp. do?
It franchises The Joint Chiropractic, a chain of US chiropractic clinics in retail centers that need no appointment and accept cash or cards rather than insurance. It had 930 clinics at September 30, 2026, almost all franchised.
What is The Joint Corp.'s revenue?
GAAP revenue from continuing operations was $54.9 million in 2025, up 5.2%, on system-wide sales of $532.4 million. Nine-month 2026 revenue rose 9.6% to $43.6 million.
How many employees does The Joint Corp. have?
Approximately 202 full-time and 128 part-time employees at December 31, 2025; more than 2,500 licensed chiropractic doctors work across the clinic network.
What is The Joint Corp.'s strategy?
Under Joint 2.0 it has become a capital-light, pure-play franchisor by selling its company-owned clinics and buying back regional developer territories. Its 2027 priority is improving comp sales, followed by Joint 3.0 expansion into new channels, B2B and new markets.
Who leads The Joint Corp.?
Sanjiv Razdan has been President and CEO since October 2024, with CFO Scott J. Bowman since June 2025.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)